Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-26-006695

Chief Executive Officer sold 139,414 shares at an average $171.30 ($23,881,618)

  • Chief Executive Officer acquired 139,414 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

TABUTEAU HERRIOT · Chief Executive Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-05 Exercise or conversion : show line 1 in the form 10b5-1 +78,703 $8.02 $631,198 85,932 D
2026-01-05 Sale : show line 2 in the form 10b5-1 −78,703 $171.28 $13,480,250 7,229 D
2026-01-06 Exercise or conversion : show line 3 in the form 10b5-1 +29,450 $8.02 $236,189 36,679 D
2026-01-06 Sale : show line 4 in the form 10b5-1 −29,450 $172.33 $5,075,119 7,229 D
2026-01-07 Exercise or conversion : show line 5 in the form 10b5-1 +31,261 $8.02 $250,713 38,490 D
2026-01-07 Sale : show line 6 in the form 10b5-1 −31,261 $170.38 $5,326,249 7,229 D
Open-market sales · 139,414 sh · avg $171.30 · $23,881,618

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2026-01-05 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −78,703 93,121 D
2026-01-06 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) −29,450 63,671 D
2026-01-07 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) −31,261 32,410 D
Loading xslF345X05/ownership.xml…